Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance.
We report a case of allergic bronchopulmonary aspergillosis (ABPA) that occurred in a man receiving infliximab for systemic sarcoidosis. His symptoms associated with ABPA were temporally related to his infliximab infusions. We suspect that infliximab disrupted the T-helper (Th) type 1-Th2 lymphocyte balance such that Th2 cytokines were left relatively unopposed, promoting the development of ABPA.
Division of Pulmonary and Critical Care Medicine, Medical University of South Carolina, Charleston, SC. Electronic address: judsonma@musc.edu.
Marc A
MA
Judson
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000139:chemically induced* / Q000276:immunology / Q000503:physiopathology; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012129:Respiratory Function Tests; D012507:Sarcoidosis / Q000188:drug therapy*; D013601:T-Lymphocytes / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D000069285:Infliximab; D011241:Prednisone